阿托伐他汀联合苯扎贝特对急性冠脉综合征患者的疗效

摘要

目的：探讨阿托伐他汀联合苯扎贝特对急性冠脉综合征（ACS ）患者调脂治疗的价值。方法：选择我院2013年4月～2013年9月收治的121例ACS患者为研究对象，根据治疗方法分为苯扎贝特组（60例，在常规治疗基础上接受苯扎贝特治疗）和联合治疗组（61例，在苯扎贝特组治疗基础上加用阿托伐他汀）。比较两组患者治疗前后总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL‐C）和高密度脂蛋白胆固醇（HDL‐C）水平，血脂达标率以及不良反应发生率。结果：治疗前两组患者各血脂指标水平差异无显著性（P＞0.05）。与治疗前比较，治疗后两组TC ，TG和LDL‐C水平均显著降低， HDL‐C水平显著升高（P＜0.05或＜0.01）；治疗后，与苯扎贝特组比较，联合治疗组TC [（4.06±0.49） mmol／L比（3.35±0.29） mmol／L]，TG [（1.60±0.33） mmol／L比（1.12±0.21） mmol／L]和 LDL‐C水平[（2.18±0.39） mmol／L比（1.91±0.26） mmol／L]显著降低， HDL‐C水平[（1.09±0.21） mmol／L比（1.26±0.26） mmol／L]显著升高， P均＜0.05；达标率：TC （41.67％比67.21％），TG （61.67％比85.25％），LDL‐C （36.67％比70.49％）和HDL‐C （41.67％比90.16％）均显著升高， P均＜0.05。两组的不良反应发生率（11.48％比10.00％）无显著差异， P＞0.05。结论：阿托伐他汀联合苯扎贝特对急性冠脉综合征患者调脂治疗，安全、效果显著。%Objective:To explore the therapeutic value of atorvastatin combined bezafibrate on adjusting lipid in pa‐tients with acute coronary syndrome (ACS) .Methods :A total of 121 ACS patients who were treated in our hospital from Apr 2013 to Sep 2013 were enrolled .According to therapeutic method ,they were divided into bezafibrate group (n=60 ,received bezafibrate treatment based on routine treatment ) and combined treatment group (n=61 , received additional atorvastatin based on treatment of bezafibrate group ) .Levels of total cholesterol (TC) ,triglyc‐eride (TG) ,low density lipoprotein cholesterol (LDL‐C) and high density lipoprotein cholesterol (HDL‐C) ,stand‐ard‐reaching rate of blood lipid and incidence rate of adverse reactions were compared between two groups before and after treatment .Results:Before treatment ,there were no significant difference in all blood lipid levels between two groups , P> 0.05. Compared with before treatment ,levels of TC ,TG and LDL‐C significantly reduced and HDL‐C level significantly rose in both groups after treatment , P< 0.05 or < 0.01 ;Compared with bezafibrate group ,there were significant reductions in levels of TC [ (4.06 ± 0.49) mmol/L vs .(3.35 ± 0.29) mmol/L] ,TG [ (1.60 ± 0.33) mmol/L vs .(1.12 ± 0.21) mmol/L] and LDL‐C [ (2.18 ± 0.39) mmol/L vs .(1.91 ± 0.26) mmol/L] ,and significant rise in HDL‐C level [ (1.09 ± 0.21) mmol/L vs .(1.26 ± 0.26) mmol/L] ,P<0.05 all;and sig‐nificant rise in standard‐reaching rates of TC (41.67% vs .67.21% ) ,TG (61.67% vs .85.25% ) ,LDL‐C (36.67%vs .70.49% ) and HDL‐C (41.67% vs .90.16% ) in combined treatment group after treatment ,P<0.05 all .There was no significant difference in incidence rate of adverse reactions (11.48% vs .10.00% ) between combined treat‐ment group and bezafibrate group , P>0.05. Conclusion:Atorvastatin combined bezafibrate can significantly im‐prove blood lipid condition and possess good safety in ACS patients .